FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has completed Phase 1 of its CDK7 inhibitor and moved into a Phase 2 breast cancer combination trial.

  • Started dosing in the Phase 2 trial of mocaciclib with fulvestrant. Source
  • Presented mocaciclib Phase 1 results at ESMO 2026. Source

Roles often seen at this stageClinical & PV · Research & development · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Qurient

A drug developer working on cancer candidates such as the CDK7 inhibitor mocaciclib and on telacebec for tuberculosis and Buruli ulcer.

Telacebec

Stage unconfirmed

A candidate for tuberculosis, Buruli ulcer and leprosy; the TREAT-BU trial supports an approval filing in Buruli ulcer.

QP101

Stage unconfirmed

A preclinical HER2-targeted dual-payload ADC candidate.

Adrisertinib (Q702)

Stage unconfirmed

A candidate prioritized for chronic graft-versus-host disease, acute myeloid leukemia and histiocytosis.

Completion reported

Finished Phase 1 dose escalation of mocaciclib and set the recommended Phase 2 dose.

Completion reported

Started dosing in a Phase 2 trial of mocaciclib with fulvestrant in HR+/HER2- breast cancer.

Completion reported

Presented mocaciclib Phase 1 results at ESMO 2026.

Official role guide

Qurient careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 큐리언트, Q901 임상 마치고 'ADC 승부수'…이중 페이로드로 확장 ↗메디파나뉴스 · Published 2026-09-15 · Sources checked 2026-11-18 · Original unavailable
  2. 큐리언트, ESMO 2026서 임상 1상 성과 공개…'모카시클립' 병용 2상 진입 ↗머니투데이 · Published 2026-07-27 · Sources checked 2026-11-18 · Original unavailable
  3. 큐리언트, ESMO 2026서 CDK7 저해제 '모카시클립' 임상 1상 결과 발표 ↗팜뉴스 · Published 2026-10-26 · Sources checked 2026-11-18 · Original unavailable